23 November 2016

Highlights in Medicinal Chemistry II

Organised by:

SCI’s Fine Chemicals Group

SCI, London, UK

Registration Closed

This event is no longer available for registration.

Synopsis
This meeting aims to showcase vignettes of modern medicinal chemistry to bring new thinking to the subject, challenge perceptions and encourage scientific interaction between researchers. The short presentation format of the meeting also aims to provide a focused forum to promote examples of medicinal chemistry excellence.
Attendees
This meeting is targeted at academic and industrial scientists engaged in all aspects of the drug discovery process and those interested in broadening their knowledge at the forefront of medicinal chemistry.

Programme

Day 1 - 23 November 2016

09:00
Registration and refreshments
09:50
Opening remarks
09:55
The realisation of activity-directed synthesis Prof Adam Nelson, University of Leeds
10:35
Structure-based design of drug-like macrocycles to probe the role of MTH1 in cancer Dr Jason Kettle, AstraZeneca
11:15
Refreshment break
11:35
Development of novel, selective and irreversible PI3K inhibitors Mr Samuel Dalton, University of Strathclyde, GlaxoSmithKline
12:00
Discovery of the first cell-active inhibitors of poly(ADP ribose) glycohydrolase (PARG) through high-throughput screening and computational approaches Dr Kate Smith, Cancer Research UK Manchester Institute
12:25
Discovery of a small molecule that mitigates hearing loss in a model of Usher syndrome III Dr Karine Malagu, Discovery from Charles River
12:50
Lunch
13:50
Discovery of novel TACE inhibitors for topical treatment of psoriasis Dr Gilles Ouvry, Galderma
14:15
Discovery of CCT251921: A potent, selective and orally bioavailable small molecule modulator of the mediator complex-associated kinases CDK8 and CDK19 Dr Aurélie Mallinger, The Institute of Cancer Research
14:40
Increasing solubility for free Dr Timothy Ritchie, TJR-Chem
15:20
Refreshment break
15:40
Extracting actionable knowledge from large scale in vitro pharmacology data Dr Al Dossetter, MedChemica
16:05
Receptor kinetics vs CNS exposure: which is more important for a ghrelin inverse agonist Dr William McCoull, AstraZeneca
16:30
Chemical probes for epigenetic proteins Prof Paul Brennan, University of Oxford
17:10
Closing remarks
17:15
Wine reception
Venue and Contact

SCI

14/15 Belgrave Square 
London
SW1X 8PS

 

Conference Team

Tel: +44 (0)20 7598 1561

Email: conferences@soci.org

Fees
Early Bird fee - before 7 October 2016

GB£90 . . . . . . . . . SCI Member
GB£40. . . . . . . . . .SCI Student Member
GB£130 . . . . . . . . Non Member

Standard fee - from 7 October 2016

GB£110. . . . . . . . .SCI Member
GB£50. . . . . . . . . .SCI Student Member
GB£155. . . . . . . . .Non Member

Become an SCI Member and save on this and future events

See Membership Options

Sign up as an Event Member to join this event. SCI Full or Student Members receive discounts on event registrations

Booking Process/Deadlines

For booking terms and conditions click here.

Sponsors
AstraZeneca
Evotec logo
Additional Info

Organising Committee

Joanne Pinder, SCI/Vertex Pharmaceuticals Eur Ltd
Sarah Major, SCI/Evotec (UK) Ltd
Iain Simpson, SCI/AstraZeneca
Mihiro Sunose, SCI/Sygnature Discovery Ltd
Nigel Swain, SCI/Pfizer

Sponsorship

If you are interested in in sponsorship opportunities, please contact conferences@soci.org.